Hyd firm develops oral insulin spray

Hyderabad-based NiedlFree Technologies has developed a painless and needle-free oral insulin spray called Ozulin. The company has applied for approval to conduct safety and toxicology studies before proceeding with human clinical trials. NiedlFree has already been granted global patents for the oral insulin and plans to raise $225-250 million to put the drug into the market. The oral insulin has demonstrated a bioavailability of over 91%, compared to the injectable route, in a recent study on dogs. The company also aims to develop oral and nasal sprays for cancer, osteoporosis, and Alzheimer’s treatment.